[1]饶燕青.理肺汤联合布地奈德福莫特罗对慢性阻塞性肺疾病患者肺功能的影响[J].医学信息,2025,38(21):87-90.[doi:10.3969/j.issn.1006-1959.2025.21.017]
　RAO Yanqing.Effect of Lifei Decoction Combined with Budesonide and Formoterol Fumarate onPulmonary Function in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2025,38(21):87-90.[doi:10.3969/j.issn.1006-1959.2025.21.017]
点击复制

理肺汤联合布地奈德福莫特罗对慢性阻塞性肺疾病患者肺功能的影响()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年21期
页码:
87-90
栏目:
论著
出版日期:
2025-11-01

文章信息/Info

Title:
Effect of Lifei Decoction Combined with Budesonide and Formoterol Fumarate onPulmonary Function in Patients with Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959（2025）21-0087-04
作者:
饶燕青
赣州经济技术开发区第二人民医院内科，江西 赣州 341000
Author(s):
RAO Yanqing
Department of Internal Medicine, Ganzhou Economic and Technological Development Zone Second People′s Hospital, Ganzhou 341000, Jiangxi, China
关键词:
理肺汤; 布地奈德福莫特罗; 慢性阻塞性肺疾病; 肺功能
Keywords:
Lifei decoction;  Budesonide and formoterol fumarate;  Chronic obstructive pulmonary disease;  Pulmonary function
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2025.21.017
文献标志码:
A
摘要:
目的 观察慢性阻塞性肺疾病患者应用理肺汤+布地奈德福莫特罗治疗的效果及对肺功能的影响。方法 以随机数字表法将2022年11月-2024年6月我院诊治的100例慢性阻塞性肺疾病患者分为两组（常规组和研究组），各组50例。常规组给予布地奈德福莫特罗治疗，研究组给予布地奈德福莫特罗+理肺汤治疗，对比两组治疗效果、肺功能指标[用力肺活量（FVC）、最大通气量（MVV）、第1 s用力呼气容积（FEV1）]、中医证候积分、CAT评分、mMRC评分、血气指标[氧分压（PaO2）、二氧化碳分压（PaCO2）]。结果 与常规组治疗总有效率的84.00%比较，研究组治疗总有效率更高，达96.00%（P＜0.05）；在肺功能指标、中医证候积分、CAT评分、mMRC评分、血气指标方面，研究组治疗后FVC、MVV、FEV1、PaO2均高于常规组，中医证候积分、CAT评分、mMRC评分、PaCO2均低于常规组（P＜0.05）。结论 理肺汤与布地奈德福莫特罗联合治疗慢性阻塞性肺疾病具有较理想的临床效果，可促进患者肺功能恢复，改善呼吸状况，减轻临床症状，有效控制病情，值得临床加以应用。
Abstract:
Objective To observe the clinical effect of Lifei decoction combined with budesonide and formoterol fumarate in the treatment of chronic obstructive pulmonary disease and its effect on pulmonary function. Methods Using the random number table method, totally 100 patients with chronic obstructive pulmonary disease diagnosed and treated in our hospital from November 2022 to June 2024 were divided into two groups, namely conventional group and study group, 50 patients per group. The conventional group was treated with budesonide and formoterol fumarate, and the study group was treated with budesonide and formoterol fumarate+Lifei decoction. The therapeutic effect, pulmonary function indexes [forced vital capacity (FVC), maximum ventilation volume (MVV), forced expiratory volume in first second (FEV1)], TCM syndrome score, CAT score, mMRC score, blood gas index [partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2)] were compared between the two groups. Results Compared with the total effective rate of 84.00% in the conventional group, the total effective rate of the study group was higher, reaching 96.00% (P<0.05). In terms of lung function indexes, TCM syndrome score, CAT score, mMRC score and blood gas indexes, the study group had higher FVC, MVV, FEV1 and PaO2 after treatment than those in the conventional group, and lower TCM syndrome score, CAT score, mMRC score and PaCO2 than those in the conventional group (P<0.05). Conclusion The combination of Lifei decoction and budesonide and formoterol fumarate in the treatment of chronic obstructive pulmonary disease has an ideal clinical effect, which can promote the recovery of pulmonary function, improve respiratory status, reduce clinical symptoms, and effectively control the disease. It is worthy of clinical application.

参考文献/References:

[1]姚晴.布地格福吸入剂治疗慢阻肺的疗效及对CRP、SaO2的影响[J].医学信息,2024,37(20):80-83.[2]梁立杰,苗苗,王键玮,等.补肺活血胶囊联合布地奈德福莫特罗吸入粉雾剂对慢性阻塞性肺疾病急性加重期合并肺动脉高压的治疗效果研究[J].中国医院用药评价与分析,2022,22(1):38-42.[3]房春丽,陈滨,王龙,等.布地奈德福莫特罗联合噻托溴铵治疗慢性阻塞性肺疾病急性加重期的临床效果[J].中国医药科学,2022,12(6):150-153.[4]Wu J,Cao M,Peng Y,et al.Research progress on the treatment of epilepsy with traditional Chinese medicine[J].Phytomedicine,2023,120:155022.[5]陈娟,冯冬婵,谭亚云,等.宽胸理肺汤联合布地奈德治疗慢性阻塞性肺疾病稳定期肺气虚证患者的疗效及对肺功能的影响[J].中华中医药学刊,2021,39(11):255-258．[6]中国老年医学学会呼吸病学分会慢性阻塞性肺疾病学组.中国老年慢性阻塞性肺疾病临床诊治实践指南[J].中华结核和呼吸杂志,2020,43(2):100-119.[7]国家卫生健康委员会急诊医学质控中心,中华医学会急诊医学分会,中国医师协会急诊医师分会,等.中国慢性阻塞性肺疾病急性加重中西医诊治专家共识(2021)[J].中华危重病急救医学,2021,33(11):1281-1290.[8]王熹,董琳,杨万春.慢性阻塞性肺病患者急性加重期低氧血症血清肌钙蛋白及心肌酶水平变化及临床意义的探讨[J].河北医学,2022,28(12):2031-2034.[9]单远莹,秦文婧,齐红松.化痰清肺汤联合布地奈德雾化吸入对慢性阻塞性肺疾病急性加重期患者外周血炎症因子及气道重塑的干预效果[J].世界中西医结合杂志,2022,17(5):931-935,940.[10]李延琴,杨丽.布地奈德福莫特罗粉吸入剂与氨茶碱片治疗缓解期慢性阻塞性肺疾病的疗效对比观察[J].山西医药杂志,2023,52(5):375-377. [11]陈欢.布地奈德福莫特罗对老年慢性阻塞性肺疾病的治疗效果[J].现代诊断与治疗,2024,35(7):989-991.[12]花荣,张家春,胡金秀.七味都气丸加味辅助布地奈德福莫特罗粉吸入剂联合噻托溴铵对重度慢性阻塞性肺疾病肺功能、血肌酐、免疫因子及T淋巴细胞亚群表达水平的影响[J].中华中医药学刊,2024,42(8):199-203.[13]孙茜.布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢性阻塞性肺疾病的疗效[J].医学信息,2022,35(20):60-62.[14]张颖超,单淑香,唐淑金,等.肺力咳合剂联合布地奈德福莫特罗治疗慢性阻塞性肺疾病急性加重期的临床研究[J].现代药物与临床,2021,36(11):2293-2298. [15]曹利静,秦海玲,李荟苹,等.细菌溶解产物胶囊联合布地奈德福莫特罗粉吸入剂对稳定期慢性阻塞性肺疾病患者的应用效果[J].河南医学研究,2023,32(4):604-607. [16]姜杉.布地奈德福莫特罗粉吸入剂联合百令胶囊对稳定期慢性阻塞性肺疾病患者血气分析、氧化应激及肺功能的影响[J].吉林医学,2022,43(1):209-211.[17]武艳,穆清爽,王惠欣,等.布地奈德福莫特罗联合三伏贴对稳定期慢性阻塞性肺疾病患者肺功能及中医症候的影响[J].湖北中医药大学学报,2022,24(1):112-114.[18]牛文哲,刘梦瑶.宽胸理肺汤合三子养亲汤治疗慢性阻塞性肺疾病急性加重期临床效果分析[J].实用中医内科杂志,2020,34(1):65-67.[19]黄芸,曹晓慧.布地奈德福莫特罗粉吸入剂治疗慢性阻塞性肺疾病患者效果观察[J].河北医药,2020,42(19):2968-2970.[20]许科科.通宣理肺颗粒联合布地奈德福莫特罗吸入剂治疗慢性阻塞性肺疾病急性发作期临床研究[J].新中医,2022,54(8):85-88.

相似文献/References:

[1]孙 茜.布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢性阻塞性肺疾病的疗效[J].医学信息,2022,35(20):60.[doi:10.3969/j.issn.1006-1959.2022.20.014]
　SUN Qian.Efficacy of Budesonide Formoterol Combined with Tiotropium Bromide Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2022,35(21):60.[doi:10.3969/j.issn.1006-1959.2022.20.014]
[2]王丽丽,石景瑜,张 敏.布地奈德福莫特罗联合噻托溴铵治疗慢阻肺稳定期的临床疗效及药理学分析[J].医学信息,2022,35(23):136.[doi:10.3969/j.issn.1006-1959.2022.23.028]
　WANG Li-li,SHI Jing-yu,ZHANG Min.Clinical Efficacy and Pharmacological Analysis of Budesonide Formoterol Combined with Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2022,35(21):136.[doi:10.3969/j.issn.1006-1959.2022.23.028]
[3]王浩凌,李冬琼,吴 旭,等.布地奈德联合噻托溴铵治疗慢阻肺的效果及对CRP、SaO2、pH水平的影响[J].医学信息,2023,36(06):143.[doi:10.3969/j.issn.1006-1959.2023.06.031]
　WANG Hao-ling,LI Dong-qiong,WU Xu,et al.Effect of Budesonide Combined with Tiotropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on CRP,SaO2 and pH Levels[J].Journal of Medical Information,2023,36(21):143.[doi:10.3969/j.issn.1006-1959.2023.06.031]
[4]孙 茜,柴明思,齐秀芳.布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢阻肺的疗效及对CRP、SaO2、pH水平影响[J].医学信息,2023,36(10):150.[doi:10.3969/j.issn.1006-1959.2023.10.033]
　SUN Qian,CHAI Ming-si,QI Xiu-fang.Efficacy of Budesonide Formoterol Combined with Tiotropium Bromide Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on CRP, SaO2 and pH Levels[J].Journal of Medical Information,2023,36(21):150.[doi:10.3969/j.issn.1006-1959.2023.10.033]
[5]刘美玲.噻托溴铵吸入剂结合布地奈德福莫特罗治疗COPD的效果及对血氧饱和度的影响[J].医学信息,2024,37(21):138.[doi:10.3969/j.issn.1006-1959.2024.21.032]
　LIU Meiling.Effect of Tiotropium Bromide Powder for Inhalation Combined with Budesonide and Formoterol Fumarate in the Treatment of COPD and its Effect on Blood Oxygen Saturation[J].Journal of Medical Information,2024,37(21):138.[doi:10.3969/j.issn.1006-1959.2024.21.032]
[6]付海燕.布地奈德福莫特罗联合噻托溴铵与布地格福对慢阻肺急性加重期患者的疗效及肺功能指标的影响[J].医学信息,2025,38(22):104.[doi:10.3969/j.issn.1006-1959.2025.22.019]
　FU Haiyan.Effect of Budesonide and Formoterol Fumarate Combined with Tiotropium Bromide and Budesonide[J].Journal of Medical Information,2025,38(21):104.[doi:10.3969/j.issn.1006-1959.2025.22.019]

更新日期/Last Update: 1900-01-01